Deepverge's Gerry Brandon (LON:DVRG) joins Proactive London's Katie Pilbeam to explain the significance of their announcement of the soft launch of a new service for their Labskin customers back in August.
Brandon reminds viewers that Labskin clones the human skin to recreate the perfect microbiome to enable real-world environment testing of products virtually.
He explains how the new R&D service builds on their existing expertise using AI technology to significantly improve speed and accuracy of testing ingredients on virtual skin models.
The soft launch in August, has already generated £400,000 in completed sales in the fourth-quarter having inked agreements with 10 new clients that had previously not used the company’s Labskin offering.